Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 169

1.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC.

Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10.

PMID:
24332241
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.

Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O'Brien S.

Lancet Oncol. 2014 Sep;15(10):1090-9. doi: 10.1016/S1470-2045(14)70335-3. Epub 2014 Aug 20.

PMID:
25150798
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH.

J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8.

PMID:
23045577
[PubMed - indexed for MEDLINE]
Free Article
4.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

PMID:
23782158
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA.

N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.

PMID:
23782157
[PubMed - indexed for MEDLINE]
Free Article
6.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
[PubMed - indexed for MEDLINE]
7.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

PMID:
24881631
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, Yuan C, Lee YS, Pedersen LB, Geisler CH, Calvo KR, Arthur DC, Maric I, Childs R, Young NS, Wiestner A.

Lancet Oncol. 2015 Feb;16(2):169-76. doi: 10.1016/S1470-2045(14)71182-9. Epub 2014 Dec 31.

PMID:
25555420
[PubMed - in process]
9.

Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.

McDermott J, Jimeno A.

Drugs Today (Barc). 2014 Apr;50(4):291-300. doi: 10.1358/dot.2014.50.4.2133570. Review.

PMID:
24918646
[PubMed - indexed for MEDLINE]
10.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
[PubMed - indexed for MEDLINE]
11.

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.

Jain N, O'Brien S.

Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006. Review.

PMID:
23915749
[PubMed - indexed for MEDLINE]
12.

Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.

Dias AL, Jain D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):265-71. Review.

PMID:
24433470
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM.

Lancet Oncol. 2013 May;14(6):472-80. doi: 10.1016/S1470-2045(13)70095-0. Epub 2013 Apr 16.

PMID:
23598171
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.

Molica S.

Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.

PMID:
24083545
[PubMed - indexed for MEDLINE]
15.

Ibrutinib: first global approval.

Cameron F, Sanford M.

Drugs. 2014 Feb;74(2):263-71. doi: 10.1007/s40265-014-0178-8. Review.

PMID:
24464309
[PubMed - indexed for MEDLINE]
16.

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.

Brown JR.

Leuk Lymphoma. 2014 Feb;55(2):263-9. doi: 10.3109/10428194.2013.803226. Epub 2013 Jun 24. Review.

PMID:
23656200
[PubMed - indexed for MEDLINE]
17.

Ibrutinib treatment of CLL: the cancer fights back.

Young RM, Staudt LM.

Cancer Cell. 2014 Jul 14;26(1):11-3. doi: 10.1016/j.ccr.2014.06.023.

PMID:
25026208
[PubMed - indexed for MEDLINE]
18.

[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].

Wang M, Xu W, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):245-9. doi: 10.7534/j.issn.1009-2137.2014.01.049. Review. Chinese.

PMID:
24598688
[PubMed - indexed for MEDLINE]
19.

Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.

Barrientos J, Rai K.

Leuk Lymphoma. 2013 Aug;54(8):1817-20. doi: 10.3109/10428194.2013.796049. Review.

PMID:
23617325
[PubMed - indexed for MEDLINE]
20.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group.

Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.

PMID:
20888994
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk